Genome sequencing Archives

Feb

February 16, 2026

Admin africanbiobank, biodiversityconservation, Genome sequencing, genomics research

MyAfroDNA Acquires Portable CycloneSEQ™ Genome Sequencer to Expand African Genomics Capabilities

MyAfroDNA, an African biotechnology company focused on advancing genomics research and innovation on the African continent, has announced the acquisition and deployment of the MGI CycloneSEQ™ genome sequencer, becoming the first facility in West Africa to deploy this advanced, portable sequencing platform.

CycloneSEQ is a cost-efficient long-read sequencing platform suitable for generating high-quality reference genomes across diverse biological systems. Its accuracy, scalable throughput, and streamlined workflows support reliable genome sequencing, assembly, and variant resolution, enabling large-scale sequencing projects with reduced per-sample cost compared to conventional long-read approaches. The system’s compact footprint and stable operation make it appropriate for sustained deployment in African research environments, facilitating locally led genome projects while strengthening regional capacity and data stewardship.

Figure 1: Photo of recently acquired CycloneSEQ genome sequencer deployed at MyAfroDNA facility in Port Harcourt, Nigeria

The CycloneSEQ™ significantly strengthens MyAfroDNA’s capacity to perform high-resolution, high-accuracy genomic sequencing, enabling applications across human health, agriculture, biodiversity, and environmental research. This milestone marks a major step toward expanding Africa’s ability to generate and analyze genomic data locally, reducing reliance on external sequencing infrastructure.

“The acquisition of the CycloneSEQ™ genome sequencer significantly strengthens our ability to generate high-quality whole-genome data locally and at scale. It allows us to support research across health, agriculture, and biodiversity, while ensuring African-led projects are powered by African infrastructure, expertise, and data ownership,” said Dr. Justin Eze Ideozu, Founder of MyAfroDNA.

Designed for precision and scalability, the CycloneSEQ™ supports whole-genome sequencing, reference genome development, population genomics, and accurate detection of genetic variants. Its flexible workflows enable MyAfroDNA to support both targeted studies and large-scale genomic projects requiring high data quality.

As part of this deployment, MyAfroDNA will immediately begin generating high-quality reference genomes to support biodiversity and conservation genomics in partnership with the African BioGenome Project (AfricaBP) and the West Africa Regional Node of the AfricaBP, Regional Center for Biotechnology and Bioresources Research (RCBBR), University of Port Harcourt, Nigeria.

“The presence of CycloneSEQ™ at MyAfroDNA is a significant development which will certainly inject life into the Endangered and Endemic Species BioGenome Project of the West African Regional node of AfricaBP. It will, as well, facilitate realization of the AfricaBP-10KP 2.0 and AfricaBP Plant Genome Projects. Hopefully, our first genome sequence will be rolled out soon. I sincerely congratulate Dr Justin Eze Ideozu and MyAfroDNA for achieving this great milestone”, said Professor Julian Osuji, AfricaBP West Africa Regional Node Coordinator and Director of the Regional Center for Biotechnology and Bioresources Research (RCBBR), University of Port Harcourt, Nigeria.

“We are happy to see the CycloneSEQ™ deployed in West Africa with MyAfroDNA. This installation represents what MGI aims to achieve globally - democratizing access to advanced sequencing technologies. We look forward to supporting MyAfroDNA and AfricaBP in their mission to sequence Africa’s endemic species by placing high-accuracy long-read capabilities directly into the hands of African researchers", said Chen Fang, General Manager of MGI Europe and Africa.

“MyAfroDNA and MGI are two strong partners of the African BioGenome Project (AfricaBP) who have demonstrated strong commitments to the African genomics and molecular biology landscape. To sequence African indigenous and endemic biological species will require intentional investments by African organisations, and I’m quite pleased (and particularly proud) to see MyAfroDNA take this bold step in acquiring the portable CycloneSEQ genome sequencer. This is a testament to the AfricaBP ecosystem in enabling partnerships, collaborations, and local investments, adding to its progress of consistently provoking local actions. The AfricaBP cannot wait to kickstart its sequencing with MyAfroDNA, and supporting biodiversity genome sequencing in Africa”, said Dr. ThankGod Echezona Ebenezer, Founder and Co-Chair, AfricaBP.

This acquisition positions West Africa as an active contributor to global genomics and life sciences research. By enabling in-region sequencing, MyAfroDNA will support universities, research institutes, conservation organizations, biotechnology companies, and policymakers with access to advanced genomic infrastructure previously unavailable in the region.

This development reinforces MyAfroDNA’s broader mission to strengthen Africa’s biotechnology ecosystem and apply genomics to real-world challenges in health, agriculture, biodiversity conservation, and environmental sustainability.

About MyAfroDNA

We are an African biotechnology company that provides solutions to the significant lack of African representation in clinical, genomics, and translational research. Contact us for questions: info@myafrodna.com

Sep

September 29, 2025

Admin african biobank, Gene editing, Genome sequencing, genomics research

Programmable Epigenome Editing with CRISPR RNPs: A Breakthrough Study

In a recent Nature Communications article, Alex M. Vakulskas, Andrew P. Goodman, Paola S. Guerena, William L. Hsieh, Benjamin M. Lane, Joseph N. Blattman, John L. Rinn, and Silvana Konermann present an innovative approach to overcoming one of the biggest challenges in epigenome editing: efficient delivery.

The team developed RENDER (Robust ENveloped Delivery of Epigenome-editor Ribonucleoproteins), a platform that packages CRISPR-based epigenome editors into engineered virus-like particles (eVLPs). Unlike viral vectors or plasmid delivery, which can pose risks of integration and cytotoxicity, RENDER delivers the editors as transient ribonucleoproteins (RNPs), ensuring high specificity and reduced off-target effects.This system was tested across a range of cell types, including iPSC-derived neurons and primary human T cells, showing durable gene silencing from a single treatment.

Remarkably, when applied to neurons carrying the MAPT V337M mutation, RENDER reduced Tau protein expression by more than 60% — a proof-of-concept with implications for treating neurodegenerative diseases.The ability to deliver programmable epigenome editors safely, transiently, and effectively represents a leap forward for gene regulation therapies. With continued optimization, this platform could accelerate progress in epigenetic drug development and broaden research applications. Click here for further reading.

At MyAfroDNA, we understand the importance of access to quality African biospecimens and molecular testing for advancing biomedical innovations like these. Partner with us to power your next research breakthrough.

Sep

September 15, 2025

Admin African genetics, african genomics, Genome sequencing

New Genomic Study Reveals Antimicrobial Resistance Genes in Staphylococcus aureus Across Africa

Antimicrobial resistance (AMR) poses a major threat to global health, and Africa is no exception. As pathogens evolve, our ability to treat common infections is becoming increasingly limited.

A new study published in Scientific Reports provides valuable insight into the genetic basis of AMR in Africa, focusing on Staphylococcus aureus, one of the most widespread and clinically significant bacteria.What the Study FoundResearchers analyzed 95 whole genomes of S. aureus collected from 11 African countries. The majority of these samples were human-derived, taken from blood, pus, urine, and wound sites.

Through bioinformatic analysis, they identified 33 antimicrobial resistance genes.Key findings include:Efflux pump mechanisms were the dominant form of resistance, allowing bacteria to actively expel antibiotics.Other resistance strategies included enzyme-mediated inactivation, target alteration, protection, and replacement.West and East Africa emerged as hotspots for the distribution of resistance genes, signaling the need for stronger surveillance in these regions.

These findings highlight the urgent need to expand genomic surveillance systems across the continent. Despite covering 11 countries, the study was limited by small sample sizes and lack of data from many African nations. This gap emphasizes the importance of building local capacity for sequencing, data analysis, and sample collection.For African health systems, this research serves as a reminder that combating AMR requires both global collaboration and homegrown solutions. Without comprehensive genomic data, it will be difficult to design effective treatment guidelines, track the spread of resistance, or prepare for future outbreaks.

At MyAfroDNA, we believe genomic research should be powered by African data, African expertise, and African innovation. Our mission is to provide high-quality biospecimens and molecular testing services that enable researchers to generate the insights needed to safeguard public health.AMR is a collective challenge, but with better data and stronger collaboration, Africa can take the lead in finding solutions.

Read the full publication here: https://www.nature.com/articles/s41598-025-01398-0

Sep

September 9, 2025

Admin african genomics, genetic research, Genome sequencing, myafrodna

New African Genomics Insights on Early Atherosclerosis

A groundbreaking study published in Nature Communications has revealed novel genetic variants associated with carotid intima-media thickness (cIMT), a key marker of early atherosclerosis, among nearly 8,000 adults from sub-Saharan Africa. The research, part of the AWI-Gen project, included participants from Burkina Faso, Ghana, Kenya, and South Africa and marks one of the largest genome-wide association studies (GWAS) on cardiovascular risk in African populations.

Two previously unidentified loci, SIRPA and FBXL17, were found to be significantly associated with cIMT, offering new insight into biological pathways involved in vascular health. Notably, the study also identified sex-specific genetic signals: SNX29 in men, and LARP6 and PROK1 in women, the latter two being enriched for estrogen response genes. These findings suggest different genetic mechanisms for cardiovascular risk between men and women.

Many of the variants identified in this African cohort are either rare or absent in European populations, emphasizing the critical need for diversity in genomic research. This study not only deepens our understanding of cardiovascular disease in African communities but also underscores the importance of building inclusive datasets to drive precision medicine. At MyAfroDNA, we champion this kind of Africa-led genomic science.

Read more on this research here: https://www.nature.com/articles/s41467-022-28276-x

Aug

August 6, 2025

Admin Genome sequencing, genomics research

Genomic Diversity in Neonatal E. coli in Malawi Raises Vaccine Design Concerns

A comprehensive genomic study of 208 neonatal Escherichia coli isolates collected from 2012 to 2021 at a major hospital in Blantyre, Malawi found extensive diversity in sequence types (STs), O‑antigens, and H‑antigens among strains causing invasive disease . Genomes from 169 isolates passed quality control and revealed 71 distinct STs, including 11 previously unreported types; over half of STs were observed only once . Among common lineages, ST69, ST131, ST10, and ST410 were most frequent, with ST410 highly enriched in cerebrospinal fluid samples suggesting invasive potential .

Researchers also catalogued 63 O‑antigen types—none exceeding 10% prevalence—and 34 H‑types, with only a handful appearing in more than one year. Notably, serotypes O15, O25B, and O8 appeared most often but no type dominated across years .

Using theoretical vaccine coverage models, the study shows that existing vaccine candidates like EXPEC4V or EXPEC9V would leave a large proportion of isolates unprotected. Crucially, the removal of O8 from some vaccine formulations could significantly reduce coverage in this setting .

Additionally, high resistance rates were observed: over 90% of strains demonstrated resistance to co‑trimoxazole, and many were multidrug resistant; yet meropenem resistance remained rare. Only amikacin and carbapenems remained reliable options in severe cases .

Implications for vaccine design in sub‑Saharan Africa: The extraordinary antigenic diversity among neonatal E. coli in Malawi presents a significant obstacle to one‑size‑fits‑all O‑antigen vaccines. The authors recommend vaccine strategies tailored to local serotype ecology and genetic surveillance integrated into design efforts.

Unlocking Africa’s Bioeconomy Through Genomics & Bioinformatics

A new study published by our partners, the AfricaBP Open Institute, showcases transformative efforts to harness biodiversity genomics and bioinformatics to drive a sustainable African bioeconomy.

The Africa BioGenome Project (AfricaBP) aims to sequence 105,000 non‑human genomes across Africa, spanning plants, animals, fungi, and protozoa, to support food security, conservation, and biotech innovation. To bridge capacity gaps, the AfricaBP Open Institute organized 31 hands‑on regional workshops in 2024 across five geographic regions, engaging participants from over 50 African countries. These sessions trained 401 African researchers in genome sequencing, gene editing, bioinformatics, molecular biology, ethics, and biobanking, strengthening local research infrastructure and skills.

A highlight case study: the proposed “1000 Moroccan Genome Project,” which illustrates economic returns from local genome sequencing. Analysis shows that a US$20 million investment over 10 years could yield US$40 million in discounted benefits and deliver a benefit–cost ratio (BCR) of 3.29—meaning every dollar invested returns more than three dollars in value—particularly across agriculture, R&D, education, and downstream sectors.

Key recommendations emerge: integrate biodiversity genomics and bioinformatics into national bioeconomy strategies, expand capacity‑building initiatives, build regional sequencing hubs, and foster ethical, inclusive data-sharing policies. Strategic investment in these domains positions African nations to capitalize on their unique biodiversity and reclaim ownership of genomic science—a powerful lever toward sustainable development and regional innovation rooted in African knowledge and priorities .

In short, AfricaBP’s model provides a scalable path for leveraging genomic science to fuel a resilient, inclusive African bioeconomy driven by regional talent and locally generated data. Read more here.

May

May 25, 2025

Admin african biobank, African genetics, dna, Genome sequencing

Revealing Morocco’s Genetic Diversity for Better Healthcare

The Moroccan Genome Project (MGP) sequenced 109 Moroccan genomes, uncovering over 27 million genetic variants, including 1.4 million new ones. This research introduces the Moroccan Major Allele Reference Genome (MMARG), providing a more accurate representation of Moroccan genetic diversity compared to global references.

By identifying unique genetic variants, MGP aims to improve precision medicine, addressing healthcare disparities for Moroccans and North Africans, especially in diseases like kidney disease, heart conditions, and diabetes.

This initiative builds on Morocco's rich genetic history and aims to create a more comprehensive genomic reference for North Africa, paving the way for better healthcare and research in the region.

Learn more here

Feb

February 10, 2025

Admin dna, Genome sequencing, genomics research

DNA Damage,Mutation and Cancer

DNA Damages Found to Last Unrepaired for Years, Leading to Mutations that Cause Cancer

This research brings our minds back to the fact that cells in our body can develop somatic mutations as a result of accumulated genetic errors in the genome. This is mostly caused by environmental exposures and other chemical reactions that occur in our cells.

This reveals that wrong copies of a genetic sequence can occur because of DNA Damage. However, there are repair mechanisms within our cells that usually recognize and mend the DNA damage quickly. by repair mechanisms in our cells. The sad part is that these DNA Damages can last unrepaired for years which brings about permanent mutations that lead to the development of various kinds of cancers.

This research reveals a better way science can think about mutations, and understand the development of various cancers. With a proper understanding of mutations leading to cancer, researchers can invent better strategies to slow or completely eradicate them.

Read the full research here.

Jan

January 13, 2025

Admin genome screening, Genome sequencing

Newborn Genome Screening: A Transformative Healthcare Intervention Strategy

Over the years, genome sequencing has improved healthcare in no small way. In recent times, researchers have found possible ways to identify potential genetic risks for thousands of diseases by simply analyzing a baby's DNA at birth.

Here are some benefits of newborn genome screening:

Early Disease Detection: Genome sequencing can detect genetic disorders before the symptoms appear, preventing serious health complications.

Personalized Care: This technology can help streamline medical care to each child's unique genetic makeup.

However, there are some important ethical considerations to be made such as privacy, consent, and the potential for unintended consequences.

As research progresses, genome sequencing holds the potential to revolutionize newborn care and improve the health and well-being of future generations.

Read more about newborn genome screening here.

Diversifying Translational and Genomics Research

Tag Archives: Genome sequencing